The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women

Rivera, Roberto; Almonte, Hector; Arreola, M; López, F. Javier; Monarrez, Griselda; Navarro, C; Ortiz, Eva; Perkin, Gordon W.; Ruiz, Raymundo Preciado

doi:10.1016/0010-7824(83)90009-4

Cited by 19 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TIBC was increased in the OC group, which has previously been reported in women using sub-50 OCs [4,6], This might be due to increased protein synthesis by the liver induced by the estrogen component of the OC. In contrast to the study of Mooij et al [6] the concentration of serum iron was not significantly different between the two groups.…”

Section: Discussionsupporting

confidence: 55%

Sub-50 Oral Contraceptives Affect Folate Kinetics

Steegers‐Theunissen

Rossum²,

Steegers³

et al. 1993

Gynecol Obstet Invest

View full text Add to dashboard Cite

The effects of long-term use of oral contraceptives containing less than 50 µg of estrogen (sub-50 OCs) on the kinetics of folic acid monoglutamate, vitamin B₁₂ levels, and iron status have been studied in 29 OC users (Marvelon®) and in 13 women without OC use serving as controls. At 210 min after oral folate loading the median serum folate concentration was significantly lower in OC users when compared to the control group. OC users showed significantly higher total iron binding capacity and significantly lower serum vitamin B₁₂ concentrations. This data demonstrates that sub-50 OCs significantly affect folate kinetics and vitamin B₁₂ levels. However, the folate and vitamin B₁₂ status does not seem to be at risk.

show abstract

Section: Discussionsupporting

confidence: 55%

Sub-50 Oral Contraceptives Affect Folate Kinetics

Steegers‐Theunissen

Rossum²,

Steegers³

et al. 1993

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…However, the effect of oral contraceptives on hematopoietic status is subject to debate. Some studies (Burton, 1967;Myo-Thein, 1969) do not observe any difference in the hemoglobin levels of women using oral contraceptives, while others, like ours, report a difference (Takkunen, 1976;Rivera, 1983;Galan, 1985).…”

Section: Discussionmentioning

confidence: 47%

Determining factors in the iron status of adult women in the SU.VI.MAX study

et al. 1998

View full text Add to dashboard Cite

The iron status of a national sample of adults living in France and participating in the SU.VI.MAX cohort, was assessed using serum ferritin and hemoglobin concentrations. Complete data were obtained for 6648 women 35 ± 60 y old and for 3283 men 45 ± 60 y old. Assessment of iron dietary intakes was realized on a subsample of 3111 women and 2337 men who reported six 24 h dietary records during a one-year period; 22.7% of menstruating women and 5.3% of post-menopausal women presented a total depletion of iron stores (serum ferritin`15 mgal). Iron-de®cient anemias were found in, respectively, 4.4% and less than 1% of these women. Three-quarters of the anemias were related to iron de®ciency in menstruating women. In men, iron depletion and iron de®ciency anemia were very rare. Post-menopausal women had much higher serum ferritin levels than menstruating women. In menstruating women, those using intrauterine devices had signi®cantly lower serum ferritin levels than those without contraception, and much lower than those using oral contraception. The frequency of iron depletion reached 28.1% in women using intrauterine devices, but only 13.6% in those using oral contraceptives. The mean iron intake was 16.7 AE 5.7 mgad in men and 12.3 AE 3.4 mgad in women. Heme iron represented respectively, 11.1 and 10.4% of iron intake. Ninety-three percent of menstruating women had dietary iron intakes lower than recommended dietary allowances (RDA); 52.6% consumed less than two thirds of these RDA. In post-menopausal women and men, respectively 27.7% and 3.6% had dietary intakes lower than RDA. Serum ferritin was positively correlated with meat, ®sh and total iron intake, and negatively correlated with dietary products consumption, calcium and ®ber intake.

show abstract

“…A majority of studies have found that combined oral contraceptives increase fibrinogen, prothrombin, FVII, FVIII and/or VWF [319–321] and, consequently, promote haemostasis. It is not known whether the increase in coagulation factors associated with combined oral contraceptives contributes to the clinical response, but combined oral contraceptives do reduce menstrual blood loss [322] and increase haemoglobin concentrations in women with anaemia [323–325]. Combined oral contraceptives, used by millions of women for prolonged periods of time, have been proven to be safe for long‐term use [326] except in women with thrombophilia [318].…”

Section: Management Of Vwdmentioning

confidence: 99%

von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)¹

et al. 2008

View full text Add to dashboard Cite

Summary. von Willebrand disease (VWD) is a commonly encountered inherited bleeding disorder affecting both males and females, causing mucous membrane and skin bleeding symptoms, and bleeding with surgical or other haemostatic challenges. VWD may be disproportionately symptomatic in women of child‐bearing age. It may also occur less frequently as an acquired disorder (acquired von Willebrand syndrome). VWD is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates platelet haemostatic function and stabilizes blood coagulation factor VIII. The pathophysiology, classification, diagnosis and management of VWD are relatively complex, but understanding them is important for proper diagnosis and management of patients with VWD. These evidence‐based guidelines for diagnosis and management of VWD from the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel (USA) review relevant publications, summarize current understanding of VWD pathophysiology and classification, and present consensus diagnostic and management recommendations based on analysis of the literature and expert opinion. They also suggest an approach for clinical and laboratory evaluation of individuals with bleeding symptoms, history of bleeding or conditions associated with increased bleeding risk. This document summarizes needs for further research in VWF, VWD and bleeding disorders, including clinical research to obtain more objective information about bleeding symptoms, advancements in diagnostic and therapeutic tools, and enhancement in the education and training of clinicians and scientists in bleeding and thrombotic disorders. The NHLBI Web site (http://www.nhlbi.nih.gov/guidelines/vwd) has a more detailed document, a synopsis of these recommendations, and patient education information.

show abstract

The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women

Cited by 19 publications

References 8 publications

Sub-50 Oral Contraceptives Affect Folate Kinetics

Sub-50 Oral Contraceptives Affect Folate Kinetics

Determining factors in the iron status of adult women in the SU.VI.MAX study

von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)¹

Contact Info

Product

Resources

About

The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women

Cited by 19 publications

References 8 publications

Sub-50 Oral Contraceptives Affect Folate Kinetics

Sub-50 Oral Contraceptives Affect Folate Kinetics

Determining factors in the iron status of adult women in the SU.VI.MAX study

von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)1

Contact Info

Product

Resources

About

von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)¹